Comparative study of a novel selective urate reabsorption inhibitor “dotinurad” among patient groups with different stages of renal dysfunction
Open Access
- 30 July 2021
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 25 (12) , 1336-1345
Abstract
Background: Dotinurad is a selective urate reabsorption inhibitor (SURI), which selectively inhibits URAT1 to lower serum uric acid levels in patients with hyperuricemia. Herein, the effects of dotinurad were compared among patient groups with different stages of renal dysfunction. Methods: Patient data from four clinical trials were pooled and divided into four groups according to the stage of renal dysfunction to compare the effects of dotinurad at different stages. The grouping (stages G1–G3b) was based on the estimated glomerular filtration rate (eGFR) of the patients. In addition, patient data from a long-term study (34 or 58 weeks) were evaluated in the same manner. Results: In the pooled analysis, the percentage of patients achieving a serum uric acid level of ≤ 6.0 mg/dL was 64.7–100.0% at a dose of 2 or 4 mg. In the long-term analysis, the percentage of patients achieving a serum uric acid level of ≤ 6.0 mg/dL was 60.0–100.0% at a dose of 2 or 4 mg. Although the outcomes in stage G3b were worse due to higher baseline serum uric acid levels, satisfactory outcomes were observed in all stages. Even in stages G3a and G3b, when renal function declined, the eGFR remained constant throughout the dose period. Conclusion: The efficacy of dotinurad was confirmed in hyperuricemic patients with normal renal function (stage G1) and mild to moderate renal dysfunction (stage G2–G3b). Dotinurad was found to be effective in the treatment of hyperuricemia in patients with mild to moderate renal dysfunction.Keywords
This publication has 12 references indexed in Scilit:
- A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without goutClinical and Experimental Nephrology, 2020
- Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without goutClinical and Experimental Nephrology, 2019
- Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 studyClinical and Experimental Nephrology, 2019
- Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 studyClinical and Experimental Nephrology, 2019
- Carnitine deficiency is associated with decreased exercise activity in hemodialysis patientsRenal Replacement Therapy, 2019
- The use survey of antihyperuricemic in cliniciansGOUT AND NUCLEIC ACID METABOLISM, 2018
- Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension studyRheumatology, 2017
- Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidneyArthritis Research & Therapy, 2016
- Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertensionHypertension Research, 2014
- Hyperuricemia Is a Significant Risk Factor for the Onset of Chronic Kidney DiseaseNephron Clinical Practice, 2014